{"filing":{"accession_number":"0001193805-26-000910","cik":"0001768224","ticker":"ARCT","company_name":"Arcturus Therapeutics Holdings Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"e665618_8k-arct.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526000910/e665618_8k-arct.htm"},"events":[{"id":15673,"run_id":13974,"accession_number":"0001193805-26-000910","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Arcturus entered into a material strategic collaboration with Thermo Fisher Scientific on June 26, 2026, comprising a Master Services Agreement and Project Addendum for CDMO and CRO services for ARCT-032 (cystic fibrosis therapy). The transaction includes up to $40 million in clinical manufacturing services and $40 million in CRO services, with Thermo Fisher receiving exclusive commercial manufacturing rights upon regulatory approval.","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13539,"accession_number":"0001193805-26-000910","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Arcturus entered into a material strategic collaboration with Thermo Fisher Scientific on June 26, 2026, comprising a Master Services Agreement and Project Addendum for CDMO and CRO services for ARCT-032. The transaction includes up to $40 million in clinical manufacturing services and $40 million in CRO services, with Thermo Fisher receiving exclusive commercial manufacturing rights upon regulatory approval. This constitutes a material definitive agreement under Item 1.01 that would affect investor assessment of the company's development strategy and commercialization pathway for a key pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T11:06:40.059438+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13540,"accession_number":"0001193805-26-000910","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Arcturus announced a strategic collaboration with Thermo Fisher Scientific to provide integrated manufacturing, clinical research, and commercial readiness services for ARCT-032 (cystic fibrosis therapy) through Phase 3 development and potential commercialization. This is a material operational/strategic partnership that advances a key pipeline program but does not constitute a merger, acquisition, or change of control (ruling out ma_activity). The collaboration is clearly operational and strategic in nature, involving outsourced CDMO and clinical research services rather than a financial transaction or governance matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T11:06:40.059438+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13539,"accession_number":"0001193805-26-000910","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"Arcturus entered into a material strategic collaboration with Thermo Fisher Scientific on June 26, 2026, comprising a Master Services Agreement and Project Addendum for CDMO and CRO services for ARCT-032. The transaction includes up to $40 million in clinical manufacturing services and $40 million in CRO services, with Thermo Fisher receiving exclusive commercial manufacturing rights upon regulatory approval. This constitutes a material definitive agreement under Item 1.01 that would affect investor assessment of the company's development strategy and commercialization pathway for a key pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T11:06:40.059438+00:00","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-07-02"},{"id":13540,"accession_number":"0001193805-26-000910","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Arcturus announced a strategic collaboration with Thermo Fisher Scientific to provide integrated manufacturing, clinical research, and commercial readiness services for ARCT-032 (cystic fibrosis therapy) through Phase 3 development and potential commercialization. This is a material operational/strategic partnership that advances a key pipeline program but does not constitute a merger, acquisition, or change of control (ruling out ma_activity). The collaboration is clearly operational and strategic in nature, involving outsourced CDMO and clinical research services rather than a financial transaction or governance matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T11:06:40.059438+00:00","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-07-02"}]}